FGFR2 (E565A)

FGFR2 · Variant type: point · HGVS: p.E565A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Futibatinib	100.0%	0.0%	98.48
2	Pralsetinib	100.0%	0.0%	93.43
3	Selpercatinib	98.1%	1.9%	96.72
4	Entrectinib	97.5%	2.5%	93.69
5	Defactinib	95.7%	4.3%	92.68
6	Fedratinib	95.3%	4.7%	96.21
7	Sunitinib	94.8%	5.2%	91.73
8	Repotrectinib	92.2%	7.8%	84.21
9	Erdafitinib	88.5%	11.5%	95.71
10	Upadacitinib	76.0%	24.0%	97.98
11	Pacritinib	75.0%	25.0%	88.64
12	Alpelisib	74.8%	25.2%	97.22
13	Pemigatinib	71.2%	28.8%	98.23
14	Avapritinib	69.4%	30.6%	97.73
15	Pexidartinib	67.2%	32.8%	99.49
16	Gilteritinib	64.6%	35.4%	88.97
17	Tivozanib	64.5%	35.5%	92.42
18	Tenalisib	53.9%	46.1%	97.98
19	Rabusertib	44.0%	56.0%	98.74
20	Deucravacitinib	43.7%	56.3%	98.99
21	Darovasertib	34.4%	65.6%	96.99
22	Neratinib	32.1%	67.9%	93.18
23	Infigratinib	27.4%	72.6%	98.24
24	Canertinib	23.7%	76.3%	96.49
25	Ripretinib	18.2%	81.8%	92.95

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Futibatinib	100.0%	99.3%	+0.7%
Pralsetinib	100.0%	93.2%	+6.8%
Selpercatinib	98.1%	95.0%	+3.1%
Entrectinib	97.5%	81.5%	+16.0%
Defactinib	95.7%	—	—
Fedratinib	95.3%	—	—
Sunitinib	94.8%	—	—
Repotrectinib	92.2%	79.8%	+12.4%
Erdafitinib	88.5%	99.0%	-10.5%
Upadacitinib	76.0%	—	—
Pacritinib	75.0%	—	—
Alpelisib	74.8%	98.9%	-24.1%
Pemigatinib	71.2%	98.7%	-27.5%
Avapritinib	69.4%	—	—
Pexidartinib	67.2%	—	—
Gilteritinib	64.6%	—	—
Tivozanib	64.5%	—	—
Tenalisib	53.9%	96.0%	-42.1%
Rabusertib	44.0%	—	—
Deucravacitinib	43.7%	92.5%	-48.8%
Darovasertib	34.4%	—	—
Neratinib	32.1%	—	—
Infigratinib	27.4%	98.8%	-71.4%
Canertinib	23.7%	—	—
Ripretinib	18.2%	85.4%	-67.1%

Cancer	Organ	Source
carcinoma_biliary_tract	Biliary Tract	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.5ms